ReviewThe AAPS journal2006
Molecular recognition of opioid receptor ligands.
Review in The AAPS journal, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Computational Methods for Understanding the Selectivity and Signal Transduction Mechanism of Aminomethyl Tetrahydronaphthalene to Opioid Receptors.Molecules (Basel, Switzerland) · 2022Article
- Chemical syntheses of the salvinorin chemotype of KOR agonist.Natural product reports · 2020Review
- Synthesis of heteroatom-containing pyrrolidine derivatives based on Ti(O-RSC advances · 2020Article
- Opioids in Gastroenterology: Treating Adverse Effects and Creating Therapeutic Benefits.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2017Review
- Allosteric modulation model of the mu opioid receptor by herkinorin, a potent not alkaloidal agonist.Journal of computer-aided molecular design · 2017Article
- Article
- Caged naloxone reveals opioid signaling deactivation kinetics.Molecular pharmacology · 2013Article
- Opioid receptor interacting proteins and the control of opioid signaling.Current pharmaceutical design · 2013Review
- Ligand-directed signalling within the opioid receptor family.British journal of pharmacology · 2012Review
- Article
- The delta opioid receptor: an evolving target for the treatment of brain disorders.Trends in pharmacological sciences · 2011Review
- Design, synthesis, and validation of a β-turn mimetic library targeting protein-protein and peptide-receptor interactions.Journal of the American Chemical Society · 2011Article
- Study of a structurally similar kappa opioid receptor agonist and antagonist pair by molecular dynamics simulations.Journal of molecular modeling · 2010Article
- "Carba"-analogues of fentanyl are opioid receptor agonists.Journal of medicinal chemistry · 2010Article
- Identification, structure-activity relationships and molecular modeling of potent triamine and piperazine opioid ligands.Bioorganic & medicinal chemistry · 2009Article
- Docking studies suggest ligand-specific delta-opioid receptor conformations.Journal of molecular modeling · 2009Article
- Conformation-opioid activity relationships of bicyclic guanidines from 3D similarity analysis.Bioorganic & medicinal chemistry · 2008Article
- Quantitative conformationally sampled pharmacophore for delta opioid ligands: reevaluation of hydrophobic moieties essential for biological activity.Journal of medicinal chemistry · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cloning of the opioid receptors and subsequent use of recombinant DNA technology have led to many new insights into ligand binding. Instead of focusing on the structural features that lead to increased affinity and selectivity, researchers are now able to focus on why these features are important. Site-directed mutagenesis and chimeric data have often been at the forefront in answering these questions. Herein, we survey pharmacophores of several opioid ligands in an effort to understand the structural requirements for ligand binding and selectivity. Models are presented and compared to illustrate key sites of recognition for both opiate and nonopiate ligands. The results indicate that different ligand classes may recognize different sites within the receptor, suggesting that multiple epitopes may exist for ligand binding and selectivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.